Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 10 Medical VC (Venture Capital) Funds in Norway in July 2025

Last updated: Jul 2025 A list of 10 VC (Venture Capital) funds that invest in Medical startups based in Norway. We rank investors based on the number of investments they made in Medical companies from Norway. We update this investor list every month.

Top 10 Medical VC (Venture Capital) Funds in Norway in July 2025

Investor	Medical Norway investments
Birk Venture	4
Hadean Ventures	1
Project Sandwater	1
HealthCap	1
Canica	1
Advent Life Sciences	1
Investinor	1
Yabeo	1
SR One	1
Advent Venture Partners	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Birk Venture is a Scandinavian venture company exclusively focusing on the life science industry.

Investment focus

Biotechnology, Medical, Health Care
Seed, Series A, Funding Round
Norway, United Kingdom

Portfolio highlights

APIM Therapeutics — APIM Therapeutics is based on an original discovery by Prof. Marit Otterlei and co-inventors at the Department of Cancer Research and Molecular Medicine at NTNU (Trondheim, Norway). The company is currently developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), a key DNA repair protein regulating cellularresponses to DNA damage and stress.
Zelluna Immunotherapy — Zelluna Immunotherapy AS is a privately owned biopharmaceutical company focused on the development of TCR based immunotherapies.
Accession Therapeutics — Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells. As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour. Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.

Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region. The funds are backed by leading private and institutional investors. Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series A, Funding Round, Series B
Sweden, Norway, Austria

Portfolio highlights

SciRhom — SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academicand industry scientists with profound experience in antibody development.
Gesynta Pharma — Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se
Alex Therapeutics — The Alex DTx Platform enables partners within pharma and health care to effectively and reliably launch new DTx treatments by leveraging existing insights, modules, processes and data.

Project Sandwater is a fresh take on venture investments within the Nordics and beyond.

Investment focus

Medical, Consulting, Life Science
Series A
Norway, The Netherlands

Portfolio highlights

Delft IMP — Delft IMP (Intensified Materials Production) commercializes nanostructuring of particles using atomic and molecular layer deposition (ALD and MLD), based on the patented and publicized IP and know-how developed within the Product & Process Engineering (PPE) group at Delft University of Technology. Following various feasibility projects betweenindustry and university, Delft IMP was initiated end 2014 to truly commercialize the technology.
Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.

HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Funding Round
United States, Sweden, France

Portfolio highlights

ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
HelloBetter — HelloBetter (hellobetter.de) was founded in 2015 under the name GET.ON Institut für Online Gesundheitstrainings GmbH (geton-institut.de) by internationally renowned research psychologists, and in close partnership with one of the largest public health care insurance companies in Germany (BARMER). HelloBetter is a pioneer in the field of e-mentalhealth and a leading provider of online mental health courses. Its work has a strong scientific basis – the courses were developed, evaluated, and implemented in a practice setting, and their effectiveness has been proven in 33 randomized controlled trials according to the highest standards of scientific practice. HelloBetter offers the widest range of evidence-based online mental health courses worldwide, with 11 digital courses covering 8 problem areas (stress, depression, insomnia, depression in the case of chronic illness, chronic pain, alcohol consumption, excessive worry, and panic and anxiety).In October 2021, the digital therapeutic 'HelloBetter Stress and Burnout' has been permanently approved by the German Federal Institute for Drugs and Medical Devices (BfArM) as a Digital Health Application (DiGA) and thus is available by prescription free of charge for more than 50 million adults. It is the world’s first and so far only prescription digital therapeutic for the treatment of burnout symptoms.Through diverse cooperations with national and international research groups (including FAU Erlangen, University of Ulm, VU Amsterdam, and Harvard University) HelloBetter finds practical applications for the latest research innovations. Our products and our team have been awarded numerous national and international prizes. These include the Novartis & Sandoz/Hexal Digital Health Prize 2018, the Comenius Award of the European Federation of Psychologists’ Association, and the Good Practice in Mental Health & Wellbeing seal of approval as part of the EU Compass 2018, which recognises high-quality mental health initiatives in Europe in order to guide health care providers to effective and proven services.
Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.

Canica is one of the largest privately owned investment companies in Norway. Our operations are focused on active, long-term ownership, primarily within sectors covering retail, fast moving consumer goods and real estate. Canica can offer core expertise within the fields of business development and finance, as well as capital and network in orderto create value and employment in a long-term perspective.

Investment focus

Beauty, Medical, Biotechnology
Private Equity, Series A, Series D
Norway, Denmark, Switzerland

Portfolio highlights

Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.
Porterbuddy — They are the gang that delivers to your door the same day you order in the online store.Porterbuddy' is a logistics platform that provides efficient and customer-centric, last-mile delivery of products.
Galecto — Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medicalneed. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.

Advent Life Sciences is a venture team investing in life sciences businesses. The team consists of 11 professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The Firm invests in a range of sectors within life sciences,principally in new drug discovery, enabling technologies, and med tech. Realizations in the last three years include Algeta, Avila, CN Creative, EUSA, Micromet. Current investments include Acutus, Biocartis, Cellnovo, f2G, NeRRe,

Investment focus

Biotechnology, Health Care, Medical
Series A, Funding Round, Series B
United States, United Kingdom, France

Portfolio highlights

Glycomine — We are developing a PMM2-CDG substrate replacement therapy. GLM101 is a mannose-1 phosphate treatment.
Arga Medtech — Novel Sine Wave Technology Promises Significant Advantages Over Existing Pulsed Field Cardiac Ablation Systems
Relief Cardiovascular — Relief Cardiovascular is an inQB8 medical technologies portfolio company developing a revolutionary smart implant to decongest heart failure patients.

Investinor invests in Norwegian based, high potential companies that are internationally oriented and in the phases ranging from early growth to expansion. The company has BNOK 4.2 ($500 m) under management and focus on companies within the internet, software, semiconductors, energy, cleantech, marine and life sciences sectors.

Investment focus

Software, Biotechnology, Manufacturing
Funding Round, Seed, Series A
Norway, United States, Switzerland

Portfolio highlights

Calluna Pharma — Join Calluna Pharma to transform therapeutics for inflammatory and fibrotic diseases. With a robust pipeline, seasoned leadership, and strategic alliances, we can revolutionize patient care.
Ignite — A powerful & easy spend management tool to accelerate your procurement success by bringing clarity, clean data & sophisticated analytics to your fingertips
Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.

We are an early-stage investor that believes in flexible Evergreen funding without the limitations of traditional funds.

Investment focus

Financial Services, Health Care, FinTech
Series A, Seed, Funding Round
Germany, United States, United Kingdom

Portfolio highlights

Yazen — Yazen is a digital obesity clinic that offers weight loss through modern pharmaceutical treatment.
WithLess — Apps multiply, costs grow, admin spirals. We get it. The tools your team needs WithLess time, money, and admin.
PIONIX — open source software as a service for charging stations / e-mobility

SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
Draig Therapeutics — Draig Therapeutics is a clinical-stage biopharmaceutical startup dedicated to creating next-generation treatments for serious neuropsychiatric illnesses.
ORIC Pharmaceuticals — ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate,ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeuticsacross a variety of solid tumors. ORIC’s second product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens. Beyond these two product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC’s scientific founders, Charles Sawyers, MD, and Scott Lowe, PhD, have long records of discovering novel targets in cancer that have led to innovative treatments.

Advent Venture Partners is one of Europe's most successful growth and venture capital investors in market-leading tech and life sciences businesses. They have designed their strategy, teams and funds so they can focus on backing a select few companies. They pride their selves on establishing true partnerships with entrepreneurs in order tobuild valuable businesses together.

Investment focus

Biotechnology, Health Care, Software
Series B, Series A, Funding Round
United Kingdom, United States, Switzerland

Portfolio highlights

Wiz — Organizations of all sizes and industries use Wiz to rapidly identify and remove the most critical risks in AWS, Azure, GCP, and Kubernetes so they can build faster and more securely.
WorldStores — Established in 2008, Worldstores is now the UK’s largest online home & garden retailer. Offering unparalleled choice, value for money, customer service and a range of convenient delivery options, Worldstores is renowned as one of the UK's most exciting e-commerce success stories.ACHICA, the luxury flash-sale business, and baby specialistKiddicare also form part of the Worldstores Group and play a key part in the ambitious plans for Worldstores Group in becoming a household name in the home and garden market.
Acutus Medical — Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists.Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Itsproducts are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals.It was founded in 2011 and headquartered in Carlsbad, California.

Investors by industry